PD-1(Hi) CAR-T cells provide superior protection against solid tumors

Chimeric antigen receptor (CAR)-T cell therapy has emerged as a promising treatment option for several hematologic cancers. However, efforts to achieve the same level of therapeutic success in solid tumors have largely failed mainly due to CAR-T cell exhaustion and poor persistence at the tumor site...

Descripción completa

Detalles Bibliográficos
Autores principales: Sailer, Cooper J., Hong, Yeonsun, Dahal, Ankit, Ryan, Allison T., Mir, Sana, Gerber, Scott A., Reagan, Patrick M., Kim, Minsoo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10303811/
https://www.ncbi.nlm.nih.gov/pubmed/37388744
http://dx.doi.org/10.3389/fimmu.2023.1187850

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10303811/
https://www.ncbi.nlm.nih.gov/pubmed/37388744
http://dx.doi.org/10.3389/fimmu.2023.1187850

Ejemplares similares